Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Bayside Health.
Recruitment status was Recruiting
University of Adelaide
Information provided by:
First received: September 13, 2005
Last updated: July 31, 2007
Last verified: September 2005
The purpose of this study is to examine gene expression profiles by DNA microarray in patients who are responders and non-responders to interferon and ribavirin treatment for hepatitis C virus (HCV). Genes involved in inflammation and fibrosis and mediators of the Th-1 lymphocyte response will be looked for. It is hoped that genetic targets for future more effective and less toxic treatments will be identified.
Procedure: Liver biopsy
||Observational Model: Defined Population
Time Perspective: Longitudinal
||Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
|Ages Eligible for Study:
||18 Years to 70 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- HCV mono-infection, no coagulopathy and having a liver biopsy for consideration of treatment
- Infection with HIV or HBV, excess ethanol (EtOH) consumption and other diseases of the liver
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00164073
|Melbourne, Victoria, Australia, 3181 |
|Contact: Mark D Berzsenyi, MBBS 0417 574 015 email@example.com |
|Principal Investigator: Mark D Berzsenyi, MBBS |
University of Adelaide
||Mark D Berzsenyi, MBBS
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 13, 2005
||July 31, 2007
||Australia: Human Research Ethics Committee
Keywords provided by Bayside Health:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 22, 2014
Hepatitis C, Chronic
Digestive System Diseases
Hepatitis, Viral, Human
RNA Virus Infections
Molecular Mechanisms of Pharmacological Action